Company: LIMN
Filing Date: 2025-07-28
Form Type: S-1/A
Source: 0001410578-25-001518
Chunk: 143

Company: Liminatus Pharma, Inc.
Filing Date: 2025-07-28
Form: S-1/A
Chunk 143
---
 | ​ |              ​ | ​ |             ​ | ​ |          ​ | ​ |       ​ | ​ |              ​ | ​ |       ​ |
| ​         |   |                 |   |             |   |                |   |               |   | Main Study |   |         | ​ | Recovery Study |   |         |
| ​         | ​ | ​               | ​ |           ​ | ​ |              ​ | ​ |          Dose | ​ |          ​ |   |       ​ |   |              ​ |   |       ​ |
| ​         | ​ | ​               | ​ |  Dose Level | ​ | Dose Volume(a) | ​ | Concentration | ​ |     No. of | ​ |  No. of | ​ |         No. of | ​ |  No. of |
| Group No. |   | Test Article    |   | -mg/kg/dose |   |         -mL/kg |   |        -mg/mL |   |      Males |   | Females |   |          Males |   | Females |
| 1         |   | Vehicle Control |   |           0 |   |                |   |             0 |   |          3 |   |       3 |   |              2 |   |       2 |
| 2         |   |                 |   |          10 |   |              2 |   |             5 |   |          3 |   |       3 |   |              — |   |       — |
| 3         |   | IBA101          |   |          30 |   |                |   |            15 |   |          3 |   |       3 |   |              — |   |       — |
| 4         |   |                 |   |         100 |   |                |   |            50 |   |          3 |   |       3 |   |              2 |   |       2 |

| ● | Study design and standards |

| ● | The 4-week toxicity study of IBA101 in Cynomolgus monkeys, conducted by Charles River Laboratories, was designed and analyzed according to GLP (Good Laboratory Practice) standards. This ensured the reliability and reproducibility of the data, adhering to rigorous quality standards throughout the study. |

| ● | Parameters and endpoints of evaluation |

Based on the most recent body